Intrathecal administration of Y-27632, a specific Rho-associated kinase inhibitor, for rat neoplastic meningitis

Molecular Cancer Research

Volumn 3, Issue 8, 2005, Pages 425-433

  Nakagawa, Hidemitsu ^a   Yoshioka, Kiyoko ^a   Miyahara, Eiji ^a   Fukushima, Yuji ^a   Tamura, Masakazu ^a   Itoh, Kazuyuki ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; AGAR; COLLAGEN TYPE 1; CYTARABINE; FLOXURIDINE; GUANINE NUCLEOTIDE BINDING PROTEIN; METHOTREXATE; MYOSIN LIGHT CHAIN; RHO KINASE; RHO KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CANCER; BRAIN STEM INJURY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CELL ADHESION; CELL MOTILITY; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; DRUG DISTRIBUTION; EXTRACELLULAR MATRIX; FEMALE; GROWTH RATE; MENINGITIS; NEOPLASTIC MENINGITIS; NEUROTOXICITY; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WALKER CARCINOMA;

ACTINS; AGAR; AMIDES; ANIMALS; BRAIN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CHEMOTAXIS; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FLOXURIDINE; GTP-BINDING PROTEINS; INJECTIONS, SPINAL; MAMMARY NEOPLASMS, ANIMAL; MENINGEAL NEOPLASMS; MENINGITIS; MICE; MICROSCOPY, FLUORESCENCE; MYOSIN LIGHT CHAINS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEURONS; OSMOSIS; PHOSPHORYLATION; PYRIDINES; RATS; RATS, WISTAR; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS;

ANIMALIA;

EID: 24144436133     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0002     Document Type: Article

References (35)

1. Giannone L, Greco FA, Hainsworth JD. Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986;4:68-73.
2. Hichin RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5:1655-62.
3. Nakagawa H, Murasawa A, Kubo S, et al. Diagnosis and treatment of meningeal carcinomatosis from solid tumors. J Neurooncol 1992;13:81-9.
4. Wasserstrom WR, Glass JP, Posner JB, Diagnosis and treatment of leptomeningeal metastases from solid tumor: experience with 90 patients. Cancer 1982;49:759-72.
5. Nakagawa H, Yamada M, Maeda M, Iwatsuki K, Hirayama A, Ikenaka K. Clinical trial of intrathecal administration of 5-fluoro-2′-deoxyuridine for treatment of meningeal dissemination of malignant tumors. J Neurooncol 1999;45:175-83.
6. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-3.
7. Norrell H, Wilson CB, Slagel DE, Clark DB. Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors. Cancer 1974;33:923-32.
8. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996;15:1885-93.
9. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for the small GTP binding protein Rho. EMBO J 1996;15:2208-16.
10. Narumiya S, Ishizaki T, Watanabe N. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett 1997;410:68-72.
11. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;6:221-5.
12. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-4.
13. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol Pharmacol 2000;57:976-83.
14. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001;33:577-81.
15. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652-9.
16. Seasholtz TM, Majumdar M, Brown JH. Rho as a mediator of G protein-coupled receptor signaling. Mol Pharmacol 1999;55:949-56.
17. Vincente-Manzanares M, Cabrero JR, Rey M, et al. A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor 1a-induced lymphocyte actomyosin and microtubular organization and chemotaxis. J Immunol 2002;168:400-10.
18. Luster AD. Chemokines-Chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
19. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-8.
20. Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000;6:102-11.
21. Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1α stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2. Cancer Res 2003;63:1969-74.
22. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001;11:471-7.
23. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GIF-binding protein RhoA promotes invasion of tumor cells. Cancer Res 1999;59:2004-10.
24. Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002;22:6570-7.
25. Fournier AE, Takizawa BT, Strittmatter SM. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 2003;23:1416-23.
26. Pollack AL, Barth AI, Altschuler Y, Nelson WJ, Mostov KE. Dynamics of β-catenin interaction with AP protein regulate epithelial tubulogenesis. J Cell Biol 1997;137:1651-62.
27. Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci U S A 2003;100:7247-52.
28. Nakanishi H, Yoshioka K, Joyama S, et al. IL-6/soluble IL-6R signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. Am J Pathol 2004;165:471-80.
29. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
31. Yoshioka K, Matsumura F, Akedo H, Itoh K. Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 1998;273:5146-54.
32. Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci U S A 1991;88:9077-81.
33. Tominaga H, Ishiyama M, Ohseto F, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 1999;36:47-50.
34. Yamada M, Nakagawa H, Fukushima M, Shimizu K, Hayakawa T, Ikenaka K. In vitro study on intrathecal use of 5-fluoro-2′-deoxyuridone (FdUrd) for meningeal dissemination of malignant brain tumors. J Neurooncol 1998;37:115-21.
35. Nakagawa H, Yamada M, Fukushima M, Ikenaka K. Intrathecal 5-fluoro-2′-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. Cancer Chemother Pharmacol 1998;43:247-56.